Adverum Biotechnologies Presents Anatomical Improvements in Intraretinal and Subretinal Fluid After a Single IVT Injection of Ixo-vec (ADVM-022) in the OPTIC Study in Wet AMD
– New data highlight that a single intravitreal injection of Ixo-vec can lead to stable and persistent aflibercept expression through three years resulting in fluid control supporting favorable vision outcomes, as well as decreasing treatment burden by an 81-98% reduction in mean annualized anti-VEGF injections
Related news for (ADVM)
- MoBot’s Stock Market Highlights – 09/23/25 11:00 AM
- Adverum Biotechnologies Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Pipeline Highlights and Updates to Anticipated Milestones
- Adverum Biotechnologies Initiates ARTEMIS Phase 3 Study Evaluating Ixo-vec for Wet AMD
- Adverum Biotechnologies Announces Positive 52-Week LUNA and 4-Year OPTIC Results, and Provides Key Pivotal Program Design Elements
- adverum biotechnologies appoints jason l. mitchell as chief commercial officer as it prepares to initiate pivotal program